content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Aduro Biotech Inc. (ADRO)

6.20
-0.10
(-1.59%)
Sep 11, 4:00PM EDT
content_middle

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. ADRO's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.

ADRO's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. ADRO's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient’s tumor.

Other Listeria strains for lung and prostate cancers are being advanced by a partner. 

Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Previous Close: 
11.65
Open: 
11.70
Bid: 
11.15
Ask: 
11.20
1yr Target Price: 
18.25
Day's Range: 
11.05 - 11.90
52wk Range: 
5.10 - 11.55
Volume: 
461256
Average Daily Volume: 
356934
Market Capitalization: 
490.17M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
79.06M
content_right

Pages